Hematology — Clinical Immunology

Red blood cell agglutinins

Red blood cell agglutinins are antibodies that bind to the surface of erythrocytes, causing them to clump together, a phenomenon known as agglutination. They fall into two broad categories according to their optimal temperature of activity: cold agglutinins, active at low temperatures (typically below 37°C), and warm agglutinins, active at normal body temperature. The clinically best-known form is cold agglutinin disease, an autoimmune hemolytic anemia in which antibodies trigger premature destruction of red blood cells by the complement system. This condition can be primary, with no identifiable cause, or secondary to infection, lymphoma or other systemic pathology. Although rare, it can significantly impair quality of life and requires specialized medical management. Its prevalence is estimated at around 16 cases per million inhabitants, with a clear predominance in people over 50.

Mechanisms and types of agglutinins

Agglutinins are distinguished by their temperature of activity, immunoglobulin class, and mechanism of erythrocyte destruction. This distinction is fundamental for guiding diagnosis and treatment.

Type	Antibody class	Operating temperature	Lysis mechanism
Cold agglutinins	IgM (mainly)	0 to 32 °C	Complement activation, intravascular hemolysis
Warm agglutinins	IgG (mainly)	98.6 °F	Opsonization, splenic phagocytosis
Mixed agglutinins	IgG + IgM	Any temperature	Combined mechanisms

ℹ️ Cold agglutinins are present at low titers in most healthy individuals and do not cause symptoms. It is their significant elevation in titer and thermal range that leads to clinical pathology.

Causes and associated conditions

Cold agglutinin disease can occur in isolation or be secondary to various underlying conditions. Identifying a treatable cause is a key step in the evaluation.

Shape	Common causes
Primary (idiopathic)	Low-grade lymphocytic clonal proliferation without defined lymphoma criteria
Secondary infectious	Mycoplasma pneumoniae, Epstein-Barr virus (mononucleosis), HIV, Hepatitis C
Secondary lymphoproliferative	Waldenstrom's lymphoma, large B-cell lymphoma, chronic lymphocytic leukemia
Autoimmune secondary	Systemic lupus erythematosus, Sjögren's syndrome

Clinical manifestations

The signs and symptoms vary depending on the severity of hemolytic anemia and the degree of vasoconstriction induced by the agglutination of erythrocytes in small vessels exposed to cold.

Fatigue, weakness, and shortness of breath with exertion related to anemia
Pale skin or yellowish complexion (jaundice) secondary to hemolysis
Acrocyanosis: bluish discoloration of the extremities (fingers, toes, ears, nose) in the cold
Raynaud's phenomenon aggravated by cold temperatures
Dark urine (hemoglobinuria) during hemolytic crises
Mild splenomegaly in some cases
Seasonal worsening of symptoms in winter

ℹ️ In Quebec, the winter climate can be a significant aggravating factor for individuals with cold agglutinin disease. Prolonged exposure to cold promotes antibody activity and can precipitate hemolytic episodes.

Diagnosis

The diagnosis is based on a battery of biological and immunological tests. The demonstration of high-titer cold agglutinins, associated with hemolytic anemia, points towards the diagnosis. Further investigations are carried out to search for a secondary cause.

Complete blood count with peripheral smear: normochromic normocytic anemia, visible erythrocyte agglutinates
Direct Coombs test: positive for C3d, negative for IgG in the classic cold form
Titration of cold agglutinins at 4°C: significant titer generally above 1/64
Hemolysis workup: high LDH, low haptoglobin, elevated indirect bilirubin
Serum protein electrophoresis and immunofixation
Mycoplasma pneumoniae and EBV serology according to clinical context
Thoraco-abdomino-pelvic CT scan for lymphoma screening
Bone marrow biopsy if hematologic malignancy is suspected

ℹ️ Red blood cell count can be skewed by erythrocyte agglutination during collection. It is recommended to transport and analyze the sample at 37°C to obtain reliable values, especially for MCV and MCHC.

Treatments

Treatment depends on the severity of the anemia, the presence of a treatable underlying condition, and the impact on quality of life. It is determined by the specialist physician based on each patient's individual profile.

Therapeutic approach	Description	Usage context
Cold avoidance	Non-pharmacological measure aimed at limiting agglutinin activation	All forms, in addition
Rituximab (anti-CD20)	Monoclonal antibody reducing IgM production by B lymphocytes	Symptomatic forms requiring treatment
Complement inhibitors (sutimlimab)	Blockade of the classical complement pathway, reducing hemolysis	Severe primary forms, recently approved
Treatment of the underlying cause	Antibiotic therapy (Mycoplasma), chemotherapy, or immunotherapy (lymphoma)	Secondary forms identified
Packed red blood cell transfusion	Reserved for severe and symptomatic anemias in the acute phase	Hemolytic emergencies

ℹ️ Corticosteroids, effective in warm antibody hemolytic anemias, are generally less effective in cold agglutinin disease due to the different erythrocyte destruction mechanism (complement rather than splenic phagocytosis).

Consult at Clinique Omicron

Clinique Omicron welcomes patients to its Quebec branches for all health-related inquiries. Our doctors provide initial clinical evaluations, coordinate laboratory tests, and refer patients to appropriate specialists when necessary. Book an appointment at the branch nearest you.

The content of this page is provided for informational purposes only and is not intended to replace the advice of a qualified healthcare professional. Consult a physician for any symptoms, questions or decisions you may have regarding your health.

Omicron Clinic

Need to consult a doctor?

Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.

No appointment necessary Private clinic Family doctor

Insurance receipts. 7j/7. No family doctor required.

At the clinic

At home

On line

Health assessments

Our programs